Gastroenterology News and Research

RSS

Gastroenterology is the branch of medicine where the digestive system and its disorders are studied.

Warner Chilcott adds $1.5 billion for senior secured credit facilities

Warner Chilcott plc today announced that it has completed an amendment to its existing senior secured credit facilities, pursuant to which it has incurred an additional $1.5 billion aggregate principal amount of new term loans

21 Aug 2010

FDA extends review on Acetadote for non-acetaminophen acute liver failure

Cumberland Pharmaceuticals Inc. today announced the U.S. Food and Drug Administration (FDA) has extended its review of the supplemental new drug application (sNDA) for the use of Acetadote® (acetylcysteine) Injection in patients with non-acetaminophen acute liver failure.

21 Aug 2010

Trial shows positive results for radioembolisation technique for colorectal cancer liver metastases treatment

Using the innovative technique of radioembolisation to treat patients with inoperable colorectal cancer liver metastases who have failed all standard-of-care chemotherapy options can more than double the time until their disease progresses, according to the final results of a Phase III randomised controlled trial published in the prestigious Journal of Clinical Oncology.

20 Aug 2010

Research on gut mucosa enables effective drug treatment for irritable bowel syndrome

Irritable bowel syndrome makes life miserable for those affected an estimated ten percent or more of the population. And what irritates many of them even more is that they often are labeled as hypochondriacs, since physical causes for irritable bowel syndrome have never been identified. Now, biologists at the Technische Universitaet Muenchen (TUM) have shed new light on the matter: They have discovered mini-inflammations in the mucosa of the gut, which upset the sensitive balance of the bowel and are accompanied by sensitization of the enteric nervous system.

20 Aug 2010

Elephant Capital and ClinTec International announce partnership deal

ClinTec International, a global Clinical Research Organisation ("CRO") announces financial and strategic partnership with Elephant Capital plc., a London AIM market listed private equity firm. With an investment of £8 Million GBP, Elephant has acquired a significant minority stake in ClinTec.

19 Aug 2010

USFDA approves Sun Pharma's generic Venlafaxine Hydrochloride Extended Release tablets ANDA

Sun Pharma announced that USFDA has granted an approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Venlafaxine Hydrochloride Extended Release tablets.

19 Aug 2010

Beaver Medical Group expands range of ophthalmological services at Banning Specialty Care Center

Beaver Medical Group is expanding the range of ophthalmological services offered at its Banning Specialty Care Center. By relocating the SCC ophthalmology services within the facility and purchasing new technology, patients will have greater access and more convenience when they need eye care.

17 Aug 2010

Cumberland Pharmaceuticals reports 9% increase in second quarter 2010 net revenue

Cumberland Pharmaceuticals Inc. ,a specialty pharmaceutical company focused on the hospital acute care and gastroenterology markets, today announces financial results for the second quarter ending June 30, 2010, and provides revenue guidance for full year 2010.

17 Aug 2010

Warner Chilcott announces issue of $750M of senior notes due 2018 in private placement

Warner Chilcott plc today announced that its subsidiaries, Warner Chilcott Company, LLC and Warner Chilcott Finance LLC, plan to issue an aggregate principal amount of $750 million of senior notes due 2018 in a private placement.

12 Aug 2010

MedThink Connect Web online communications tool enables face-to-face interaction with experts

MedThink Communications, a full-service healthcare communications company, today announced the launch of MedThink Connect™, a new, customizable Web application that provides healthcare companies a vehicle to efficiently seek guidance, maintain interaction, and build a community atmosphere with external experts. MedThink Connect allows users to advance their relationships with external experts, including advisors, investigators, spokespeople, patients, and speakers.

12 Aug 2010

Trigemina reports positive results from TI-001 Phase IIa clinical trial for Chronic Daily Headache

Trigemina, Inc., a Mountain View, CA based pharmaceutical company, reports positive results from its Phase IIa proof-of-concept clinical trial for TI-001 in Chronic Daily Headache. The trial is a collaborative effort between Trigemina and Dr. Egilius Spierings of MedVadis Research Corporation located outside of Boston, and compares intranasal TI-001 with placebo in patients suffering from CDH.

11 Aug 2010

Vertex reports results from Phase 3 ILLUMINATE study of telaprevir-based therapy for hepatitis C

Vertex Pharmaceuticals Incorporated today announced results from the Phase 3 ILLUMINATE study, which was designed to evaluate whether there was any benefit to extending therapy from 24 to 48 weeks in people whose hepatitis C virus (HCV) was undetectable at weeks 4 and 12 of treatment (extended rapid viral response or eRVR).

10 Aug 2010

FDA accepts Salix's XIFAXAN550 sNDA for Priority Review

Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Company's efficacy supplement to the New Drug Application (NDA) for XIFAXAN® (rifaximin) 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome (Non-C IBS) and IBS-related bloating.

9 Aug 2010

Scientific findings reveal combination antibiotic therapy effective for ulcerative colitis

The link between Hormone Replacement Therapy and reduced risk of distal large bowel cancer in women; a promising combination antibiotic therapy for ulcerative colitis patients; and the high-rate of alcoholic liver disease mortality, are among the scientific findings featured in the August issue of The American Journal of Gastroenterology.

6 Aug 2010

Studies show biological agents play important role in maintaining remission in Crohn's disease

Biological agents may play an important role in maintaining remission in Crohn's disease, according to two new studies in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association Institute.

6 Aug 2010

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Repligen Corporation today reported results for the first quarter of fiscal year 2011, ended June 30, 2010. Total revenue for the first quarter was $7,010,000 compared to total revenue of $5,061,000 for the first quarter of fiscal year 2010, an increase of $1,949,000 or 39%. Bioprocessing product revenue for the first quarter was $4,269,000 compared to $2,473,000 for the first quarter of fiscal 2010, an increase of $1,796,000 or 73%.

5 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

New trend in management of post-liver transplantation biliary strictures

Endoscopic intervention has emerged to become the first line treatment for benign biliary strictures following liver transplantation. The current endoscopic approach involves repetitive dilatation of the stricture and placement of multiple large-diameter parallel plastic stents with frequent stent exchange to prevent biliary infection.

3 Aug 2010

PHD1 useful for pharmacologic inhibition in IBD: Research

Research into inflammatory bowel disease (IBD) led by UCD Conway Institute scientists with national and international collaborators has identified a key regulator involved in maintaining the functional integrity of the gut lining. The findings, published recently in the scientific journal, Gastroenterology, provide information that may be important in developing a new therapeutic approach to the treatment of the disease.

3 Aug 2010

Study explores role of genetic influence on ulcerative colitis

Adults diagnosed with ulcerative colitis after age 50 are more likely to achieve remission from their symptoms than patients diagnosed at younger ages, even when those patients receive similar treatments, according to research at Washington University School of Medicine in St. Louis.

3 Aug 2010

Gastroenterology News and Research

Further Reading

Warner Chilcott adds $1.5 billion for senior secured credit facilities

FDA extends review on Acetadote for non-acetaminophen acute liver failure

Trial shows positive results for radioembolisation technique for colorectal cancer liver metastases treatment

Research on gut mucosa enables effective drug treatment for irritable bowel syndrome

Elephant Capital and ClinTec International announce partnership deal

USFDA approves Sun Pharma's generic Venlafaxine Hydrochloride Extended Release tablets ANDA

Beaver Medical Group expands range of ophthalmological services at Banning Specialty Care Center

Cumberland Pharmaceuticals reports 9% increase in second quarter 2010 net revenue

Warner Chilcott announces issue of $750M of senior notes due 2018 in private placement

MedThink Connect Web online communications tool enables face-to-face interaction with experts

Trigemina reports positive results from TI-001 Phase IIa clinical trial for Chronic Daily Headache

Vertex reports results from Phase 3 ILLUMINATE study of telaprevir-based therapy for hepatitis C

FDA accepts Salix's XIFAXAN550 sNDA for Priority Review

Scientific findings reveal combination antibiotic therapy effective for ulcerative colitis

Studies show biological agents play important role in maintaining remission in Crohn's disease

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

New trend in management of post-liver transplantation biliary strictures

PHD1 useful for pharmacologic inhibition in IBD: Research

Study explores role of genetic influence on ulcerative colitis

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News